Evommune, Inc. Current Liabilities
Evommune, Inc. (EVMN) had Current Liabilities of $17.49 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Liabilities, Current $17.49M.
- 2026-03-31: Liabilities, Current $10.60M.
- 2025-12-31: Liabilities, Current $17.91M.
- 2025-09-30: Liabilities, Current $10.42M.
| Period end | Liabilities, Current |
|---|---|
| 2026-06-30 | $17.49M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $10.60M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $17.91M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $10.42M 10-Q · filed 2025-12-11 |
| 2024-12-31 | $27.98M 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |